• 1
    di Salle E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, Panzeri A, Delos S, Martin P. PNU 157706, a novel dual type I and II 5α-reductase inhibitor. J Steroid Biochem Mol Biol 1998; 64: 17986.
  • 2
    Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, Teh CZ, Dreon DM, Paffenbarger RS,Jr. Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 73541.
  • 3
    Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, Boyle P, Hopper JL. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11: 54953.
  • 4
    Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. II. Androstenedione metabolism in isolated hairs. J Clin Endocrinol 1974; 39: 101219.
  • 5
    Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in a man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 121315.
  • 6
    Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression. J Clin Invest 1993; 92: 90310.
  • 7
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 111826.
  • 8
    Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 12629.
  • 9
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 8691.
  • 10
    Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW. Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 1992; 90: 799809.
  • 11
    Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-Americans and Hispanic men in Los Angeles, USA. Lancet 1999; 354: 9758.
  • 12
    Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 1997; 57: 10202.
  • 13
    Ntais C, Polycarpou A, Ioannidis JPA. SRD5A2 gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 61824.
  • 14
    Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5 α-reductase type II genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 1859.
  • 15
    Allen NE, Reichardt JKV, Nguyen H, Key TJ. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomarkers Prev 2003; 12: 57881.
  • 16
    Kakinuma H, Tsuchiya N, Habuchi T, Ohyama C, Matsuura S, Wang L, Nakamura A, Kato T. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Prostate Cancer Prostatic Dis 2004; 7: 3337.
  • 17
    Ellis JA, Panagiotopoulos S, Akdeniz A, Jerums G, Harrap SB. Androgenic correlates of genetic variation in the gene encoding 5α-reductase type 1. J Hum Genet 2005; 50: 5347.
  • 18
    Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5α-reductase genes. J Invest Dermatol 1998; 110: 84953.
  • 19
    Giles GG, Severi G, McCredie MR, English DR, Johnson W, Hopper JL, Boyle P. Smoking and prostate cancer: findings from an Australian case-control study. Ann Oncol 2001; 12: 7615.
  • 20
    Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, Hopper JL. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003; 95: 81824.
  • 21
    Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 135965.
  • 22
    Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, Sutherland RL, Hopper JL, Giles GG. The E211 G>A androgen receptor polymorphism is associated with decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 2005; 14: 9936.
  • 23
    Sham P. Statistics in human genetics. London: Arnold, 1998.
  • 24
    Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995; 29: 31122.
  • 25
    Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1:The analysis of case-control studies. Lyon: IARC, 1980. IARC publication no. 32.
  • 26
    Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK. Steroid 5-α reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev 2002; 11: 41718.
  • 27
    Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS. Association of prostate cancer risk and aggressiveness to androgen pathway genes; SRD5A2, CYP17 and the AR. Prostate 2004; 59: 6976.
  • 28
    Forrest MS, Edwards SM, Houlston R, Kote-Jarai Z, Key T, Allen N, Knowles MA, Turner F, Ardern-Jones A, Murkin A, Williams S, Oram R, et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 95102.
  • 29
    Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. The 5α-reductase type II A49T and V89L high-activity alleleic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005; 48: 67985.
  • 30
    Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JKV. Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostattic hyperplasia and prostate cancer. Urol Oncol 2005; 23: 24653.
  • 31
    Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A. 5α-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002; 12: 30712.
  • 32
    Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000; 60: 162630.
  • 33
    Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 11307.
  • 34
    Mononen N, Ikonen T, Syrjakoski K, Matikainen M, Schleutker J, Tammela TL, Koivisto PA, Kallioniemi OP. A missense substitution A49T in the steroid 5-α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 2001; 84: 13447.
  • 35
    Stanczyk FZ, Bretsky P. Biosynthesis, transport, and metabolism of steroid hormones. In: Henderson BE, Ponder B, Ross RK, eds. Hormones, genes, and cancer. New York: Oxford University Press, 2003. 1237.
  • 36
    Ellis JA, Harrap SB. The genetics of androgenetic alopecia. Clin Dermatol 2001; 19: 14954.
  • 37
    Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116: 4525.